WebArun Upadhyay is the Chief Scientific Officer at Ocugen. Additionally, Arun Upadhyay has had 1 past job as the SVP and Head of R&D at Ocugen. Ocugen Chief Scientific Officer Sep 2024. Organization Name . Title At Company . Start Date . End Date . Ocugen . SVP and Head of R&D: Dec 2024: 2024: Related Hubs. Web28 feb 2024 · Ocugen, Inc. filed its 10-K on Feb 28, 2024 for the period ending Dec 31, 2024. ... Arun Upadhyay: Chief Scientific Officer: Robert J. Hopkins: Chief Medical Officer: Jesse Simmers: Head-IT & Facilities: More about the company. Sector and Competitors. 1st jan. Capi. (M$) OCUGEN, INC.
Did you know?
Web14 apr 2024 · -- Ocugen a déclaré vendredi que sa thérapie génique expérimentale, OCU400, présentait un profil d'innocuité favorable et des améliorations visuelles lors … WebRamesh Kumar. Founder of Onconova Therapeutics, Inc., Ramesh Kumar is on the board of Ocugen, Inc. and Ocugen OpCo, Inc. In the past he was Chief Executive Officer & Director at Onconova Therapeutics, Inc., Scientist at Bristol Myers Squibb Co., President-Genomics & Transgenics Division at Kimeragen, Inc., Principal at Princeton University and ...
Web2 giorni fa · Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research, Development & Medical, Ocugen Huma Qamar, MD, MPH, Head of Clinical Development and Medical … Web14 apr 2024 · “The early results from patients treated in the Phase 1/2 clinical trial are encouraging and support the paradigm-changing potential of modifier gene therapy technology to address unmet medical needs for patients with RP and LCA,” said Arun Upadhyay, PhD, Chief Scientific Officer and Head of Research, Development and …
Web28 mar 2024 · Ocugen公司(Ocugen或该公司)(纳斯达克代码:OCGN)今天宣布，FDA批准在正在进行的OCU400期试验中招募儿科患者。 Ocugen首席科学官Arun Upadhyay博士指出:“这一批准使我们在将OCU400(一种新的基因不可知修饰基因疗法)作为一种潜在的改变患有遗传性视网膜疾病(如RP和LCA)儿童生活的治疗方法推向市场的努力中又 ... Web2 giorni fa · MALVERN, Pa., April 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, …
Web8 nov 2024 · Modifier gene therapy platform has potential to treat multiple retinal diseases with one productMALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical ...
Web2 giorni fa · Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research, Development & Medical, Ocugen Huma Qamar, MD, MPH, Head of Clinical Development and Medical Affairs, Ocugen allie abraham neWeb2 giorni fa · Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research, Development & Medical, Ocugen Huma Qamar, MD, MPH, Head of Clinical Development and Medical … allie 2022WebArun UPADHYAY, PostDoc Position Cited by 763 of University of Colorado, CO (UCD) Read 12 publications Contact Arun UPADHYAY allie 100Web2 giorni fa · Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research, Development & Medical, Ocugen. Huma Qamar, MD, MPH, Head of Clinical Development and Medical Affairs, Ocugen. David Birch, PhD, Scientific Director, Retina Foundation of the Southwest, primary investigator of the study. Neena B. Haider, PhD, Fellow of ARVO and inventor of … allie acresWeb6 apr 2024 · Unternehmensprofil. Ocugen, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Gentherapien zur Heilung von Erblindungskrankheiten und die Entwicklung eines Impfstoffs für COVID-19 konzentriert. Die Technologie-Pipeline des Unternehmens umfasst: COVID-19-Impfstoff (0,5), Modifier-Gen-Therapie-Plattform und … allie acnhWeb6 apr 2024 · 27.03. Ocugen, Inc. gibt Fda-Zulassung für die Aufnahme pädiatrischer Patienten in die laufende klinische Phase-1/2-Studie Ocu400 zur Behandlung von Retinitis Pigmentosa (Rp) und Leber Congenital Amaurosis (Lca) bekannt allie accountWeb29 apr 2024 · Presentation Title: OCU410, a Potential Therapeutic for Dry-AMD, Suppresses Inflammatory Cytokine Gene Expression in Retinal Pigment Epithelial Cells Authors: Dinesh K. Singh, Sree S. Kattala, Arun K. Upadhyay Presentation Type: Poster Session Presenter: Dinesh K. Singh, Principal Scientist, Discovery Date/Time: May 1, 2024, from 12:15 – … allie abney